Cargando…

Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report

The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Tony Zibo, Harik, Lara, Force, Seth, Hadadi, Agreen, Bilen, Mehmet Asim, Brown, Jacqueline T., Carthon, Bradley C., Goldman, Jamie, Kucuk, Omer, Master, Viraj A., Nazha, Bassel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755666/
https://www.ncbi.nlm.nih.gov/pubmed/36530969
http://dx.doi.org/10.3389/fonc.2022.949400
_version_ 1784851466182197248
author Zhuang, Tony Zibo
Harik, Lara
Force, Seth
Hadadi, Agreen
Bilen, Mehmet Asim
Brown, Jacqueline T.
Carthon, Bradley C.
Goldman, Jamie
Kucuk, Omer
Master, Viraj A.
Nazha, Bassel
author_facet Zhuang, Tony Zibo
Harik, Lara
Force, Seth
Hadadi, Agreen
Bilen, Mehmet Asim
Brown, Jacqueline T.
Carthon, Bradley C.
Goldman, Jamie
Kucuk, Omer
Master, Viraj A.
Nazha, Bassel
author_sort Zhuang, Tony Zibo
collection PubMed
description The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radical nephrectomy and metastasectomy of known pulmonary disease site, both without a clinical need for perioperative blood transfusions. The patient continues to be without evidence of disease and without additional need for systemic therapy over a year after his radical nephrectomy. The case highlights that cytoreductive nephrectomy continues to play a role in the era of immune checkpoint inhibitors.
format Online
Article
Text
id pubmed-9755666
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97556662022-12-17 Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report Zhuang, Tony Zibo Harik, Lara Force, Seth Hadadi, Agreen Bilen, Mehmet Asim Brown, Jacqueline T. Carthon, Bradley C. Goldman, Jamie Kucuk, Omer Master, Viraj A. Nazha, Bassel Front Oncol Oncology The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received two cycles of nivolumab/ipilimumab followed by radical nephrectomy and metastasectomy of known pulmonary disease site, both without a clinical need for perioperative blood transfusions. The patient continues to be without evidence of disease and without additional need for systemic therapy over a year after his radical nephrectomy. The case highlights that cytoreductive nephrectomy continues to play a role in the era of immune checkpoint inhibitors. Frontiers Media S.A. 2022-12-02 /pmc/articles/PMC9755666/ /pubmed/36530969 http://dx.doi.org/10.3389/fonc.2022.949400 Text en Copyright © 2022 Zhuang, Harik, Force, Hadadi, Bilen, Brown, Carthon, Goldman, Kucuk, Master and Nazha https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhuang, Tony Zibo
Harik, Lara
Force, Seth
Hadadi, Agreen
Bilen, Mehmet Asim
Brown, Jacqueline T.
Carthon, Bradley C.
Goldman, Jamie
Kucuk, Omer
Master, Viraj A.
Nazha, Bassel
Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
title Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
title_full Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
title_fullStr Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
title_full_unstemmed Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
title_short Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
title_sort durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a jehovah’s witness: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755666/
https://www.ncbi.nlm.nih.gov/pubmed/36530969
http://dx.doi.org/10.3389/fonc.2022.949400
work_keys_str_mv AT zhuangtonyzibo durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport
AT hariklara durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport
AT forceseth durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport
AT hadadiagreen durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport
AT bilenmehmetasim durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport
AT brownjacquelinet durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport
AT carthonbradleyc durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport
AT goldmanjamie durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport
AT kucukomer durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport
AT masterviraja durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport
AT nazhabassel durablecompleteresponseforoligometastaticrenalcellcarcinomawithimmunecheckpointinhibitionandcytoreductivenephrectomyinajehovahswitnessacasereport